In a phase 1 clinical trial of GPRC5D-targeted CAR-T (MCARH109) showed that a response was reported in 71% (12/17) of the MM patients and 35% (6/17) achieved CR, 59% (10/17) achieved VGPR or better [69]. This evidence concerns the gene GPRC5D and Miyoshi myopathy.